Sort
51,593 grants matching “hepatitis”
Spatio-temporal Methods for Surveillance of the Opioid Syndemic
$2,260,761David M Kline · Wake Forest University Health Sciences · R01 · FY2025 · DA
Regulation of hepatic and systemic immune responses
$2,260,571Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
COBRE Center for Cancer Research Development
$2,260,550Bharat Ramratnam · Rhode Island Hospital · P20 · FY2012 · GM
Hepatitis Animal Models
$2,256,885Cornell University · N01 · FY2008 · AI
Griffithsin-based Rectal Microbicides for PREvention of Viral ENTry (PREVENT)
$2,255,692Kenneth E Palmer · University Of Louisville · U19 · FY2017 · AI
Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study
$2,255,132Jennifer R Havens · University Of Kentucky · R01 · FY2019 · DA
Childhood Liver Disease Research Network Data Coordinating Center
$2,254,971John C Magee · University Of Michigan At Ann Arbor · U01 · FY2018 · DK
IeDEA Asia-Pacific Research Collaboration
$2,253,765Annette H Sohn · Foundation For Aids Research · U01 · FY2019 · AI
Molecular Mechanisms of Pathogenesis of Acute and Chronic Liver Diseases
$2,252,657Patrizia Farci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
COBRE Center for Cancer Research Development
$2,251,971Bharat Ramratnam · Rhode Island Hospital · P20 · FY2011 · RR
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS
$2,250,354University Of North Carolina Chapel Hill · U01 · FY2000 · AI
HIV Neurobehavioral Research Center
$2,249,742Igor Grant · University Of California, San Diego · P30 · FY2006 · MH
VACCINATION AGAINST INTRAPARTUM HIV CLADE C TRANSMISSION
$2,248,304Dana-Farber Cancer Institute · P01 · FY2002 · AI
GENERAL CLINICAL RESEARCH CENTER
$2,247,575Scripps Research Institute · M01 · FY2000 · RR
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,243,861Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2024 · AG
Griffithsin-based Rectal Microbicides for PREvention of Viral ENTry (PREVENT)
$2,242,842Kenneth E Palmer · University Of Louisville · U19 · FY2018 · AI
Chicago Consortium Women's Interagency HIV Study lll
$2,241,084Mardge H Cohen · Hektoen Institute For Medical Research · U01 · FY2007 · AI
NORTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
$2,238,755Northwestern University · U01 · FY2003 · AI
The Johns Hopkins University - Uganda Clinical Trials Unit
$2,237,197Mary Glenn Fowler · Johns Hopkins University · UM1 · FY2021 · AI
Hepatobiology and Toxicology COBRE
$2,236,038Craig J McClain · University Of Louisville · P20 · FY2024 · GM
Clinical Genomics and Experimental Therapeutics
$2,235,970Falk Lohoff · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2025 · AA
Mindful Body Awareness Training as an Adjunct to Medication Assisted Treatment for Opioid Use Disorder: An ancillary study
$2,235,261Cynthia J Price · University Of Washington · R01 · FY2019 · AT
United States Military HIV Research Program (MHRP) Clinical Trials Unit
$2,234,831Robert A. Gramzinski · Walter Reed Army Institute Of Research · UM1 · FY2019 · AI
Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study
$2,233,828Jennifer R Havens · University Of Kentucky · R01 · FY2021 · DA
Translational Multimodality " Antibody" Therapy
$2,232,495University Of California Davis · P01 · FY2005 · CA